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Abstract
Effect of long-term (90–100 days) exposure of rats to soluble salt of aluminum (AlCl3) on myelin
lipid profile was examined. The long-term exposure to AlCl3 resulted in a 60 % decrease in the total
phospholipid (TPL) content while the cholesterol (CHL) content increased by 55 %. Consequently
the TPL / CHL molar ratio decreased significantly by 62 %. The phospholipid composition of the
myelin membrane changed drastically; the proportion of practically all the phospholipid classes
decreased by 32 to 60 % except for phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
Of the latter two, proportion of PC was unchanged while PE increased in proportion by 47 %.
Quantitatively, all phospholipid classes decreased by from 42 to 76% with no change in the PE
content. However the membrane fluidity was not altered in Al-treated rats. Many of the changes
we observe here show striking similarities with the reported phospholipid profiles of Alzheimer
brains.
Introduction
Loss of short-term memory marks the beginning of Alzhe-
imer's disease (AD) and the condition ultimately leads to
progressive dementia [1-7]. This involves memory loss,
disorientation and impairment of judgement and reason-
ing [1-7]. Pathologically, abnormally high deposits of
senile plaques comprising β-amyloid protein and, neu-
rofibrillary tangles in specific brain regions have been
reported [4,8,9]. In later stages of AD reduced levels of
neurotransmitters and extensive neuronal and synaptic
loss are the common biochemical features [2,3,6,10-13].
Specifically, there is a selective loss of acetylcholine releas-
ing neurones in the basal forebrain, hippocampus and
cortex [12,13]. Impaired cholinergic function in AD has
been correlated with loss of memory [2,6,10,12].
Amongst the various hypotheses concerning AD [2,7,14-
16], the membrane hypothesis [7,16] and the one impli-
cating aluminum (Al) as a possible environmental etio-
logic factor [7,15,17-22] are of considerable interest.
Neurotoxicity from exposure to Al is known to result in
impairment of learning memory and cognition function
both from clinical observations and from animal experi-
ments [5,14,15,17,23]. Crapper et al. reported that the
concentrations of Al in the brains of AD patients were sig-
nificantly high [23]. Long-term administration of soluble
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salt of Al to rats worsens their learning ability together
with diminished cholinergic function and the rats become
lethargic [14,15,17,23]. Role of Al intoxication in neuro-
degenerative diseases has been recently emphasized
[18,24-29].
Earlier studies from our laboratories have shown that pro-
longed treatment with AlCl3 given in the diet caused sig-
nificant impairment of energy metabolism in the rat brain
mitochondria [19]. In parallel studies, we also noted that
this treatment resulted in decreased proportion and con-
tent of phospholipid classes in the rat brain microsomal
and synaptic plasma membranes [30,31]. Importance of
myelin membrane for insulation is well documented [32].
It was therefore of interest to find out if prolonged treat-
ment with AlCl3 can affect the myelin lipid profile. The
findings of these investigations are summarized in the
present communication. The results of our present studies
show that indeed the prolonged exposure to AlCl3
resulted in significant changes in content and composi-
tion of phospholipid classes and in cholesterol content of
the rat brain myelin. It is possible that this altered lipid /
phospholipid content and composition could affect the
insulation properties of the myelin. The finding may thus
have some bearing on loss of short-term memory in
Alzheimer's disease.
Materials and Methods
Chemicals
Silica gel G was purchased from E. Merck, Germany and
1,6 diphenyl-1,3,5 hexatriene (DPH) was purchased from
Sigma, U.S.A. All other chemicals were of analytical – rea-
gent grade and were purchased locally.
Animals and treatment with Al
Adult male albino rats (100–120 g, 6–7 week old) of
Charles-Foster strain were given in their diet 100 mg of
AlCl3 /kg body weight /day for 90 to 100 days [19,30,33].
The animals were weighed every week and accordingly the
dose of AlCl3 was adjusted on weekly basis. The animals
in control group were given equivalent amounts of NaCl.
The regimen for Al treatment is described in detail in [30].
We have earlier shown that under these conditions, com-
pared to controls, in the experimental group the Al body
burden is about 2.2 times higher throughout the experi-
mental period [30].
Isolation of myelin
At the end of the treatment period, the animals were killed
by decapitation and their brains were quickly dissected
out and kept in beakers containing chilled (0 to 4°C) 0.25
M sucrose. Isolation of myelin from 20 % (w/v) homoge-
nates was according to the procedure of Burgyone and
Rose [34], as described [30,35], which is based on discon-
tinuous sucrose density gradient centrifugation. Briefly,
after the removal of nuclei and cell debris at 600 × g for 10
min., the combined mitochondrial-synaptosomal-myelin
fraction was sedimented by centrifugation at 10,000 × g
for 10 min. The resulting pellet was then subjected to
hypotonic lysis using 5 ml of 5 mM Tris-HCl buffer pH
8.1. After incubation at 0°C for 30 min., the lysate was
mixed with 5.0 ml of 80 % (w/w) sucrose, transferred to a
to a centrifuge tube of a Beckman SW 28.1 rotor and was
carefully over layered with 10.0 ml of 28.5% (w/w)
sucrose, followed by 8.0 ml of 10% (w/w) sucrose. The
tubes were then subjected to centrifugation at 60,000 × g
for 1.5 hr. The myelin fraction banding at the top of the
gradient was carefully removed, resuspended in 0.25 M
sucrose and re-sedimented by centrifugation at 100,000 ×
g for 40 min. in a TFT80 rotor. The resulting pellets were
suspended in 0.25 M sucrose to give a final protein con-
centrations of 2–3 mg / ml. All operations were carried out
at 0–4°C.
The isolated myelin fraction showed only negligible Na+,
K+_ ATPase activity [35].
Lipid analysis
Extraction of total lipids [36], and estimations of choles-
terol and phospholipid phosphorus were by the proce-
dures described [37,38]. The phospholipid classes were
separated by thin layer chromatography [39]. The detailed
procedures have been described earlier [30].
Membrane fluidity measurements
Measurements of membrane fluidity were carried out at
25°C in a Shimadzu RF 5000 spectrophotoflourimeter
using 1,6 diphenyl-1,3,5 hexatriene (DPH) as the probe as
described in details earlier [30].
Protein estimation was according to the method of Lowry
et al.,[40].
Statistical evaluation of the data was by Student's 't'-test.
Results
Data in Table 1 show that long-term exposure of rats to Al
resulted in 60% decrease in the total phospholipid (TPL)
content of the myelin membrane while the cholesterol
(CHL) content increased by 55%. Consequently the
molar ratio of TPL / CHL decreased significantly. How-
ever, the yield of myelin protein was almost comparable
in the two groups and was around 7–8 mg protein / g
brain (wet wt.). The results thus emphasize that long-term
exposure to Al brought about significant qualitative and
quantitative changes in lipid composition (Table 1) with-
out affecting myelin protein content.
We then analyzed the phospholipid composition of the
myelin membrane. These data are given in Table 2. OurLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/13
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values for the control group are in close agreement with
those reported by others [32,41]. Thus phosphatidyleth-
anolamine (PE) and phosphatidylcholine (PC) are the
major phospholipids(37 and 28 % respectively) of myelin
while the other components ranged from 5 to 9%. Al
treatment resulted in generalized decrease (32 to 60%
decrease) in all the phospholipid classes except for PC and
PE. Of the latter two the PC was unchanged while the PE
component had increased by 47%. The quantitative data
on contents of individual phospholipid classes are given
in a Table 3, which show that prolonged Al treatment
resulted in a generalized decrease in the content of all the
phospholipid classes from 42–76% except for PE which
was unchanged. Measurements of membrane fluidity
however revealed that in spite of significant composi-
tional changes in the lipid/phospholipids content and
composition (Tables 1,2,3), the membrane fluidity was
not altered in the Al-treated rats. Thus the values for the
Table 1: Effect of long-term Al feeding on the total phospholipid and cholesterol content of myelin membrane in the rat brain.
Animals TPL (µg/mg protein) CHL (µg/mg protein) TPL/CHL (mole : mole)
Control(6) 1357.4 ± 136.4 785.1 ± 36.5 0.86 ± 0.07
Al-fed(8) 824.7 ± 95.8* 1222.1 ± 104.9** 0.33 ± 0.04***
The rats weighing 100–120 g were given in their diet 100 mg AlCl3 / kg body weight / day for 90–100 days [19,30,33] as described in the text. 
Results are given as mean ± SEM of the number of observations indicated in the parentheses. * p < 0.01, ** p < 0.005, *** p < 0.001.
Table 2: Effect of long-term Al feeding on phospholipid composition of myelin membrane in the rat brain.
Phosoholipid Class Phospholipid composition (% of total) Change (%)
Control(24) Al-fed(18)
Lyso 5.85 ± 0.61 3.53 ± 0.28* -39.7
SPM 9.29 ± 0.52 6.31 ± 0.38** -32.1
PC 27.63 ± 1.51 26.12 ± 0.78 -5.5
PS 6.18 ± 0.78 3.28 ± 0.29* -46.9
PI 8.96 ± 0.83 3.58 ± 0.46** -57.7
PE 37.48 ± 1.00 55.20 ± 1.58** +47.3
PA 5.33 ± 0.38 2.20 ± 0.33** -58.7
Experimental details are as described in the text and in Table 1. Results are given as mean ± SEM of the number of observations indicated in the 
parentheses. ** p < 0.002, * p < 0.001.
Table 3: Effect of long-term Al feeding on phospholipid content of individual phospholipids of myelin membrane from the rat brain.
Phosoholipid Class Phospholipid content (µg / mg protein) Change (%)
Control(24) Al-fed(18)
Lyso 79.46 ± 8.18 28.74 ± 2.79* -63.8
SPM 125.86 ± 9.83 52.86 ± 4.69* -58.0
PC 376.08 ± 28.18 216.56 ± 15.77* -42.4
PS 84.36 ± 9.65 26.69 ± 2.72* -68.4
PI 121.74 ± 10.89 29.61 ± 3.63* -75.7
PE 506.86 ± 33.36 456.06 ± 33.18 -10.0
PA 71.39 ± 6.13 18.04 ± 2.41* -74.7
Experimental details are as described in the text and in Table 1. The contents of individual phospholipid classes was computed from the TPL 
content and composition for the respective sample. Results are given as mean ± SEM of the number of observations indicated in the parentheses. * 
p < 0.001.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/13
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fluorescence polarization (P), fluorescence anisotropy (r),
limited hindered anisotropy (r∝) and order parameter (S)
were: 0.254 ± 0.008, 0.186 ± 0.006, 0.148 ± 0.008 and
0.612 ± 0.006 respectively for the controls; these values
did not differ significantly in Al-treated animals (Table 3).
Discussion
From the foregoing results it is clear that Al-treatment
resulted in significant reduction in the phospholipid con-
tent accompanied by major compositional changes,
which is consistent with membrane hypothesis of AD
[2,16]. According to this hypothesis, in order to make up
for the choline deficiency, the neurons try to extract
choline from choline containing phospholipids. This
results in the disruption of cell membranes and ultimately
in neuronal cell death [2]. From the data presented
(Tables 2 and 3), it is clear that this decrease occurred in
both sphingomyelin (SPM) and PC with the effect being
more pronounced on the former component. In related
studies we have observed that in the synaptic plasma
membranes also the content of SPM decreased signifi-
cantly in Al-treated rats, while the effect on PC component
was of lesser magnitude [30,31]. Taken together, the
results would suggest that PC is relatively more important
for membrane function than SPM and that choline for
neurotransmitter synthesis may be extracted in the first
instance from SPM component. The results thus comple-
ment the membrane hypothesis of AD [2]. The other
interesting feature of our observation is a decrease of
greater magnitude in the contents of the acidic
phospholipids viz. phosphatidylserine (PS), phosphati-
dylinositol (PI) and phosphatidic acid (PA), while con-
tent of the major basic phospholipid i.e. PE did not
change (Tables 2 and 3). Decrease in the PI in the brains
of the AD patients has already been reported [42-44]. The
net result of the compositional changes we observe here
(Tables 2 and 3) would be the altered charge distribution
in the myelin membrane. The phospholipids are known
to be asymmetrically distributed in the two membrane
leaflets [45]. Thus the net decrease in the negative charges
and relatively lesser decrease in the positive charges that
we find here could have major influence on the insulation
properties of the myelin membrane. One more interesting
features is the decrease in the lysophospholipids (Lyso)
and PA which is indicative of decreased phospholipid
turnover. We have nothed earlier, similar pattern for rat
brain synaptic plasma membranes and microsomes [30].
In this connection, it is of interest to note that in the
brains of AD patients the lysophospholipase activity
increased significantly [42,44], and lysophosphospholi-
pid acyl transferase activity increased [42,44]. This will
correlate well with our observation on decreased Lyso
content (Tables 2 and 3).
The result of our present studies, taken together with our
earlier observations on synaptic plasma membranes and
microsomes [30] suggest that long-term exposure to Al
specifically alters the brain lipid/phospholipid metabo-
lism and/or their transfer to various membrane systems.
Al may affect these processes by various mechanisms such
as creating energy deficiency [19], forming a complex with
ATP where the Al-ATP complex is energy compromised
[18], or by affecting the functions of various enzymes
[15]. Role of Al-ATP complex in Ca2+ mediated excitotox-
icity and neurotoxicity will ultimately results in neuronal
cell death is well recognized, as is the requirement of
phospholipases for Ca2+ [18]. Al is known to replace metal
ions in many enzyme systems [15] which in turn could
influence the lipid/phospholipid metabolism. Addition-
ally we have shown earlier that prolonged exposure to Al
resulted in decreased rates of substrate oxidation in rat
brain mitochondria. In particular, the cytochrome oxidase
activity decreased significantly [19]. A similar decrease in
cytochrome oxidase activity in the brains of AD patients
has been reported [46].
Roth et al. [16] have reported that reconstituted mem-
brane from the brain lipids of AD patients were thin due
to decreased cholesterol content. This is in contrast with
our observation that the cholesterol content was actually
higher in Al-fed rats. (Table 1) However it may be pointed
out that Roth et al.,[16] were reporting on the lipid profile
of the whole brain regions, whereas we are dealing with
purified membrane system. In related studies, we have
found that the cholesterol content of the microsomes
decreased after Al-treatment [30,31]. It is thus likely that
overall average content of cholesterol of the whole brain
might have decreased as reported by Roth et al.[16]; mye-
lin may be a special case where increased cholesterol con-
tent may be a compensatory mechanism to ensure the
insulation properties following significant alterations in
phospholipid profiles (eg. see Tables 2 and 3). We have
already shown earlier that changes in lipid/phospholipid
profiles drastically impaired the synaptic plasma mem-
brane Na+, K+- ATPase activity [31] which will get com-
pounded further due to compromised energy
transduction and Al-ATP complex formation referred to
above [18,19]. Additionally, the Vmax of cerebral
acetylcholinesterase decreased significantly under these
experimental conditions [47]. Obviously, these factor will
result in impaired signal transmission while the lipid/
phospholipid changes in myelin would alter the insula-
tion properties.
Despite the significant changes in lipid / phospholipid
profiles (Tables 1,2,3), the membrane fluidity was not
altered in the Al-treated group. The molar ratios of TPL/
CHL, PC/PE and SPM/PE are the accepted indexes of
membrane fluidity [48,49]. Thus increase in the latter twoLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/13
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indicates decreased fluidity, whereas the opposite is true
for the TPL/CHL molar ratio [48]. From the data given in
Tables 1 and 2, it is clear that the TPL/CHL molar ratio
decreased which will decrease the fluidity. However the
PC/PE and SPM/PE molar ratios decreased which will
increase the fluidity. Thus it is possible that the two oppo-
site effects might have counterbalanced each other and
hence there is no apparent net change in membrane fluid-
ity parameters. Interesting to note in this connection is the
fact that DPH monitors only the bulk membrane fluidity
[50]. Altered membrane fluidity in platelets from AD
patients has been reported [43,51], which is in contrast to
our present observations. However once again these
authors [43,51] were measuring the fluidity of the whole
cells which can not be extrapolated to purified myelin
membrane system described here.
It is well recognized that cerebrosides are major compo-
nent of myelin [52]. It is possible that long-term Al expo-
sure might have caused alterations even in the content of
the cerebrosides in the myelin. However in the present
studies, we have not looked at this possibility; further
investigations along these lines could provide useful
information. Interesting to note in this context is the
observation that Al under in vitro conditions increased
lipid peroxidation only of the galactolipids [53].
In conclusion, results of our present studies have brought
into focus several parallels in the myelin membrane lipid
alterations in Al-treated rats and the AD brains [16,42,44].
Such changes in turn can affect the insulation properties
leading to memory and cognition dysfunctions which is a
common feature of AD [1-7]. The clues that we get from
rat studies reported here suggest that it might be of interest
to enquire and investigate whether similar changes occur
in the myelin membranes in the AD patients.
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